6月25日，长城基金公告将诺辉健康估值由停牌前价格大幅下调91.51%，至1.20港元/股。这是继2024年7月调整至7.48港元/股后的再度下调。业内人士指出，多家基金公司相继调低估值，反映出对诺辉健康复牌前景的悲观预期。曾被誉为‘癌症早筛第一股’的诺辉健康如今估值近乎归零，也揭示了部分生物科技公司在高增长叙事背后的合规风险。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.